Literature DB >> 10234701

Brachytherapy boost techniques for locally advanced prostate cancer.

F A Vicini1, L L Kestin, J S Stromberg, A A Martinez.   

Abstract

Brachytherapy boosts in combination with external-beam radiation therapy allow a highly conformal dose of radiation to be delivered to the prostate in a safe, efficient manner. Several types of brachytherapy boost techniques are used currently. Techniques based on transrectal ultrasound (TRUS) guidance clearly provide the most accurate method of radioactive source placement with reduced toxicity. Temporary implants employing remote afterloading systems with high-dose-rate (HDR) brachytherapy offer the added advantage of further optimizing dose distribution after needle placement. Novel brachytherapy programs using intraoperative real-time dosimetric analyses provide additional options for performing truly conformal dose escalation. Results with these newer boost techniques appear to be as good as or better than other forms of therapy in comparably staged patients. Until standardized methods of reporting treatment data are uniformly applied and longer follow-up is obtained with other treatment modalities, brachytherapy boosts combined with external-beam radiation should be considered an acceptable treatment option for patients with locally advanced prostate cancer. The challenge for the future will be to determine which treatment approach is optimal given certain critical pretreatment prognostic factors. In addition, the role of adjuvant androgen deprivation in controlling this malignancy will be critical and awaits the results of several recently initiated or completed randomized trials.

Entities:  

Mesh:

Year:  1999        PMID: 10234701

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

Review 1.  Bicalutamide: in early-stage prostate cancer.

Authors:  Christopher I Carswell; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Is there room for combined modality treatments? Dosimetric comparison of boost strategies for advanced head and neck and prostate cancer.

Authors:  Joanna Góra; Johannes Hopfgartner; Peter Kuess; Brigita Paskeviciute; Dietmar Georg
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

3.  Preclinical evaluation of cationic DOTA-triarginine-lipid conjugates for theranostic liquid brachytherapy.

Authors:  Wenbo Wang; Frederikke P Fliedner; Anders E Hansen; Rasmus Eliasen; Fredrik Melander; Andreas Kjaer; Thomas L Andresen; Andreas I Jensen; Jonas R Henriksen
Journal:  Nanotheranostics       Date:  2020-04-22

4.  Comparison of two treatment approaches for prostate cancer: intensity-modulated radiation therapy combined with 125I seed-implant brachytherapy or 125I seed-implant brachytherapy alone.

Authors:  Yulin Song; Maria F Chan; Chandra Burman; Donald Cann
Journal:  J Appl Clin Med Phys       Date:  2008-03-18       Impact factor: 2.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.